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The conventional method for quantitating Mycobacterium tuberculosis (Mtb) in vitro and
in vivo relies on bacterial colony forming unit (CFU) enumeration on agar plates. Due to
the slow growth rate ofMtb, it takes 3–6 weeks to observe visible colonies on agar plates.
Imaging technologies that are capable of quickly quantitating both active and dormant
tubercle bacilli in vitro and in vivo would accelerate research toward the development
of anti-TB chemotherapies and vaccines. We have developed a fluorescent probe that
can directly label the Mtb cell wall components. The fluorescent probe, designated as
DLF-1, has a strong affinity to the D-Ala-D-Ala unit of the late peptidoglycan intermediates
in the bacterial cell wall. We demonstrate that DLF-1 is capable of detecting Mtb in both
the actively replicating and dormant states in vitro at 100 nM without inhibiting bacterial
growth. The DLF-1 fluorescence signal correlated well with CFU of the labeled bacteria
(R2 = 1 and 0.99 for actively replicating and dormant Mtb, respectively). DLF-1 can
also quantitate labeled Mtb inside of cells. The utility of DLF-1 probe to quantitate Mtb
was successfully applied to identify genes critical for cell invasion. In conclusion, this
novel near infrared imaging probe provides a powerful new tool for enumerating Mtb
with potential future use in bacterial virulence study.
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INTRODUCTION
With more than three deaths per minute, tuberculosis (TB) is a major public health threat.
Approximately 9 million new cases of TB are identified per year, with 1.5 million deaths related
to TB (WHO, 2015), making TB the greatest cause of mortality due to a bacterial pathogen.
The majority of individuals infected with Mtb develop latent TB infection (LTBI) where bacteria
and the host have established equilibrium without causing apparent symptoms in the host. In
LTBI, Mtb can persist in host lungs or other tissues for months to decades without replication.
Abbreviations: TB, tuberculosis; Mtb, Mycobacterium tuberculosis; CFU, colony forming unit; ITC, isothermal titration
calorimetry; PBS, Phosphate buffered saline; MOI, Multiplicity of infection; PG, peptidoglycan; AG’ arabinogalactan; MA,
Mycolic acid; D-Ala-D-Ala, D-alanyl-D-alanine.
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Approximately one third of the world population has been
latently infected byMtb (Sudre et al., 1992). Because LTBI can be
reactivated upon immune suppression, the infected individuals
serve as a huge reservoir of active TB in the community.
Eliminating latent TB cases would help to reduce active TB
significantly.
Research on TB has been impeded by the slow growth rate of
Mycobacterium tuberculosis (Mtb), the major causative pathogen
of TB. Conventionally, quantification of Mtb in vitro and in
vivo relies on counting bacterial colony forming units (CFU)
on agar plates. Mtb divides every 15–20 h. It takes several
weeks for Mtb to form visible colonies on solid agar plates
(Glickman and Jacobs, 2001; Smith, 2003; Zumla et al., 2013).
Imaging technologies that are capable of quickly quantitating
tubercle bacilli in vitro and in vivo would greatly accelerate
research toward the development of anti-TB chemotherapies and
vaccines.
Both bioluminescent and fluorescent protein labeled
Mycobacterium spp. have been developed for quantitating
bacteria in TB research (Andreu et al., 2010, 2012, 2013; Carroll
et al., 2010; Kong et al., 2010; Zelmer et al., 2012; Zhang et al.,
2012; Ollinger et al., 2013; Singh et al., 2014; Vocat et al., 2015),
a number of which have been applied to in vivo imaging of
M. tuberculosis infection (Andreu et al., 2010, 2013; Kong
et al., 2010; Zelmer et al., 2012; Zhang et al., 2012). By using
non-invasive fluorescent-imaging technologies as laboratory
tools to track Mtb in vitro and in animals, infections can be
visualized in real-time. Although recombinant reporter strains
have been used for imagingMtb infection (Andrew and Roberts,
1993; Cooksey et al., 1993; Arain et al., 1996; Hickey et al., 1996;
Heuts et al., 2009) in vitro and in vivo, expression of a foreign
gene can impact bacterial fitness (Coulson et al., 1994; Wendland
and Bumann, 2002; Rang et al., 2003) or sometimes even be toxic
to bacteria (Andreu et al., 2010).
In this study, we developed a fluorescent-imaging strategy
that labels macromolecular components of the TB cell wall.
This long wavelength fluorescent-imaging probe designated as
direct labeling fluorescence-1 (DLF-1), is shown to be highly
quantitative. DLF-1 is capable of detecting Mtb in both actively
replicating and non-replicating dormant states in vitro. DLF-1
can also quantitate labeledMtb harbored in cells. In addition, we
have successfully verified that DLF-1 can be applied to identify
bacterial genes critical for cell entry. This novel imaging probe
provides a powerful new tool for quantitating actively replicating
and dormantMtb in vitro.
MATERIALS AND METHODS
Synthesis of DLF-1
Et3N (15.2 mL, 0.109 mmol), oxyma (4.7mg, 0.0328mmol), and
EDCI (6.3mg, 0.0328mmol) were added to a stirred solution of
vancomycin (32.5mg, 0.0219mmol) and Boc-Gly-OH (4.6mg,
0.0263mmol) in DMF (0.2mL). After being stirred for 22 h
at room temperature, the reaction mixture was filtered. The
filtrate was purified by reverse phase HPLC to afford Boc-Glycyl-
vancomycin (85% yield). 0.1 mL of 4.0 M HCl (dioxane solution)
was then added to a stirred solution of Boc-Glycyl-vancomycin
(3.9 mg, 2.39 mmol) in dioxane (0.1 mL). After 4 h at room
temperature, all volatiles were removed under reduced pressure
to afford HCl-Glycyl-vancomycin. Et3N (1.0 mL, 7.32 mmol)
and cyanin5.5 NHS ester (0.52 mg, 0.732 mmol) in DMF (0.1
mL) were added to a stirred solution of HCl-Glycyl-vancomycin
in DMF (0.1 mL). After 6 h at room temperature, all volatiles
were removed under reduced pressure to afford the crude DLF-1.
This was purified by reverse phase HPLC to afford DLF-1 (>95%
purity).
Verification of DLF-1 Binding to PG Using
Isothermal Titration Calorimetry (ITC)
Binding of bacterial PG peptide to vancomycin or DLF-1
was monitored using an ITC200 (Microcal, Piscataway, NJ).
Vancomycin hydrochloride from Streptomyces orientalis (32
µM final concentration, V2002, Sigma) or DLF-1 (7 µM
final) was diluted in 1X PBS pH 7.4 (21-040-CM, Corning),
and 204 µL was loaded into the cell. Experiments contained
1% DMSO (BP-231, Fisher) in both syringe and cell, to aid
solubility. Peptide Ac-L-Lys-D-Ala-D-Ala was dissolved in the
same buffer (600 or 100 µM, respectively), and 39.4 µL
was loaded in the syringe. For each binding, three separate
experiments were conducted at 25◦C (298.15K). Injections were
performed with serial injections of peptide; first, one injection
of 1 µL, followed by 19 incremental injections of 2 µL, at
120 s intervals. Data from the first injection was excluded,
due to pre-equilibration mixing between the contents of cell
and syringe at the syringe tip. Peak areas were integrated,
normalized, and then fitted by non-linear regression using the
independent sites model in OriginTM (version 2.3.6, Microcal,
Piscataway, NJ).
Bacterial Growth Curves in the Presence or
Absence of DLF-1
The mycobacterium strains (M. smegmatis, M. bovis BCG, and
Mtb) were started from −80◦C stocks. For M. bovis BCG, and
Mtb, cultures growth in the presence or absence of DLF-1 were
performed in 7H9 broth (Difco, Detroit, MI) supplemented
with 0.5% glycerol, 10% oleic acid dextrose complex without
catalase and 0.05% Tween 80 (MOAD/T medium) at 37◦C
without shaking. The bacterial cultures were then started in the
presence of different concentrations of DLF-1 (0, 100 nM, 1 µM)
and monitored OD over time in a 96-well plate with a Tecan
multimode reader (Infinite 200 Pro, Tecan) at absorbance 600
nm with bandwidth 9 nm and number of flashes as 25. OD was
measured daily forM. bovis BCG andMtb to plot growth curves.
For M. smegmatis, culture was set up in a 96-well plate, and the
plate was kept in the reader at 37◦C. OD was measured hourly
with automatic shaking for 10 min before ODmeasurement. The
Supplementary Figure 1 shows the correlation between the OD
values measured with the Tecan microplate reader at 600 nm
and the OD value in a cuvette measured with commonly used
ThermoScientific Genesys 20 spectrophotometer (ThermoFisher
Scientific) at 600 nm, which helps convert the OD values of the
Tecan microplate reader into OD values in a cuvette measured
with the Genesys 20.
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MIC of DLF-1 against M. smegmatis
Minimum inhibitory concentration of DLF-1 against M.
smegmatis at which 90% of strains were inhibited (MIC90) was
determined using the standard broth microdilution method in
96-well microtiter plates as described previously with minor
modifications (Swenson et al., 1982). Briefly, serial doubling
dilutions of DLF-1 were prepared in MOAD broth to achieve
final concentrations ranging from 8 to 0.125µg/ml.M. smegmatis
was added to each well with a final inoculum of ∼105 CFU/ml.
The plate was incubated at 37◦C. OD600 was measured at 48 h
with a Tecan microplate reader. The wells with M. smegmatis
alone were controls.
Direct Labeling Bacteria with DLF-1
Bacterial cultures were stopped when they reached the
logarithmic growth phase (OD600, 0.4∼0.6). For each strain of
studied bacteria, a series of dilutions were made starting from
OD600 of 1.0 measured with Genesys 20 in growth medium.
Bacteria cells were centrifuged at 9000 rpm for 5 min, and cell
pellets were washed with 1X PBS twice and finally resuspended in
1X PBS containing 100 nMDLF-1 for 3 h on ice (for fast-growing
M. smegmatis) or at room temperature (for M. bovis BCG and
MtbCDC1551). After incubation with DLF-1, bacterial cells were
centrifuged (9000 rpm, 5 min), washed once with 1X PBS (10,000
rpm, 10 min) to remove unbound DLF-1, and were finally
resuspended in equal volumes of 1X PBS solutions. Each sample
was added to a fluorescence 96-well microplate, and fluorescence
intensity of DLF-1 was measured with a multimode fluorescence
plate reader (InfiniteR 200 PRO, Tecan) at excitation 680 nm
and emission 710 nm. Each strain of bacteria was also titrated to
enumerate CFU. For determination of threshold of detection, we
optimized the condition of the Tecan reader, with gain value as
150, excitation 670 nm and emission 700 nm. For cell infection,
a series of concentrations of a tdTomato-expressing Mtb strain
were incubated with 100 nM DLF-1, then were used to infect
THP-1 macrophages and A549 human lung epithelial cells.
Fluorescence was measured 3-h post infection by the Tecan plate
reader.
Fluorescent Microscopy of DLF-1 Labeled
Mtb Inside Cells
A tdTomato expressing Mtb strain (Erdman-pJDC60) was
applied to infect cells after labeling bacteria with DLF-1. This
strain was cultured in MOAD/T medium with addition of 25
ug/ml kanamycin until it reaches the logarithmic phase (OD600,
0.4∼0.6). A549, or THP-1 cells were grown on the coverslips in
24-well cell culture plates at a concentration of 2× 105 cells/well.
For THP-1, phorbol 12-myristate 13-acetate (PMA) was used to
stimulate the cells for 3 days. The cells were then infected with
bacteria at 37◦C for 3 h. After bacterial infection, extracellular
bacteria were aspirated, and the infected cells were washed with
1X PBS, treated with amikacin (200 µg/ml) for additional 2 h
to eliminate extracellular bacteria as described previously (Mehta
et al., 1996; Napier et al., 2011). Bacterium infected cells were then
fixed with 4% freshly made paraformaldehyde for 10 min at room
temperature. After washing with 1X PBS for three times, the
fixed infected cells were permeabilized with 0.2% Tween-80/PBS
(v/v) solution for 5 min, washed again with 1X PBS for three
times, and then stained with DAPI solution (300 nM) for 5 min
in the dark. After another three-time washing with 1X PBS, the
coverslips containing bacterium infected cells were taken out and
mounted to glass slides for fluorescence microscopy analysis with
a deconvolution microscope (Carl Zeiss). For imaging of DLF-1
labeled dormantMtb inside macrophages, aMtb CDC1551 strain
carrying a genome integrated tdTomato gene (CDC1551-pYK13)
was cultured in a modified Wayne non-replicating persistence
model. THP-1 cells seeded in a 24-well plate containing cover
slips were stimulated with PMA for 3 days, and then infected
with the DLF-1 (100 nM) labeled, non-replicating td-Tomato-
expressing Mtb. After bacterial infection, the same protocols of
DAPI staining, slide mounting, and microscopy imaging were
conducted. Images were taken with a 63X oil lens.
Construction of a Mtb Strain Carrying a
Genome-Integrated tdTomato Gene
We constructed a tdTomato-expressing Mtb in a more stable
manner by site-specifically integrating a single copy tdTomato
into the mycobacterial chromosome, using a mycobacterial
plasmid containing the phage attachment site attP and the L5
integrase (int) gene from the mycobacteriophage L5 genome, as
has been shown by others for bioluminescent reporters (Andreu
et al., 2010, 2013). To construct this vector, we began with
replacing the GFP gene in pFJS8, an E. coli-mycobacterium
shuttle plasmid containing the L5 promoter (Miltner et al.,
2005), with a fragment from pDONR222 (Invitrogen) containing
a suicide ccdB gene and a chloramphenicol resistance gene
(CmR) at restriction sites of HindIII/KpnI. In this way, the
expressions of ccdB and CmR are under a L5 promoter. We then
cut the L5-ccdB- CmR fragment from the new vector at XhoI
and KpnI and ligated it into XhoI/KpnI digested pYUB412, a
mycobacterial integrating cosmid vector (Bange et al., 1999).
The tdTomato gene was then PCR amplified from pRSETB-
tdTomato using an up-stream primer containing HindIII site
at 5′ end and a down-stream primer containing KpnI site at 5′
end (F: 5′-TATAAAGCTTGGATCCATGGTGAGCAAGG-3′; R:
5′-TATAGGTACCGAATTCTTACTTGTACAGCTCGTCC-3′).
The purified PCR product was then digested with HindIII and
KpnI and ligated into the HindIII/KpnI digested pYUB412
containing L5-ccdB- CmR. The new plasmid is designated as
pYK13. After transformation of the pYK13 into CDC1551, we
selected colonies with hygromycin selective agar plates, and
confirmed the success of integration of tdTomato into Mtb
genome by PCR amplifying the tdTomato and hygromycin
resistance genes, and by the presence of tdTomato specific
fluorescence.
Non-replicating Persistence Model
We modified the Wayne non-replicating persistence (hypoxic
shift-down) model by substituting Dubos with 7H9 (containing
0.05% Tween 80 and 10% OAD) and using the Mtb strain
expressing genome-integrated tdTomato (CDC1551-pYK13).
Mtb cultures were set up at 105–106 cfu/ml in 12 × 75 mm
tubes in a total volume of 3.0 mL (head space ratio, HSR = 0.5).
Each tube contained a 13 × 4 mm diameter stir bar (Fisher,
PA, USA). Cultures were incubated in a 37◦C incubator on a
stir plate with 200 rpm. Some cultures also contained Methylene
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Blue at a concentration of 1.5 mg/L to be used as an indicator
of oxygen depletion. An additional tube of Methylene Blue
withoutMtb was used as a color reference. When the Methylene
Blue-containing tube turned colorless, cultures were incubated
for an additional week (total 18–22 days), and then were used
for DLF-1 fluorescence labeling. A sample of the culture was
carefully removed from the middle portion of each tube by
pipette to avoid disturbing the pellicle on the surface or the
sediment on the bottom. Optical density reading (600 nm) of
the cultures was determined. A series of dilutions were made
and then centrifuged (9000 rpm, 5min), washed once with 1X
PBS/T, and then resuspended in 1X PBS. DLF-1 labeling of
the dormant cultures were performed similarly as for labeling
of other bacteria before. The Mtb CDC1551 strain carrying a
genome-integrated tdTomato gene was cultured in the Wayne
model to reach dormant state, diluted in various concentrations,
and then labeled with DLF-1. Fluorescent intensity of DLF-1
labeled dormant Mtb was plotted against the concentration of
bacteria or concentration of DLF-1, respectively. All conditions
were set up in triplicates. Samples of dilutions were taken for CFU
enumeration on 7H10 agar plates in duplicates. Colonies were
enumerated at 4–6 weeks following inoculation.
Using DLF-1 Labeling to Identify Genes
Important for Cell Invasion
Mtb transposon mutant of plcC, CDC1551, 1hbhA and MT103
strains were cultured in MOAD/T medium. Bacterial cells
grown to middle-logarithmic phase (OD600 nm , 0.4∼0.6) were
harvested, labeled with 100 nM DLF-1 at room temperature
for 3 h, washed and suspended in antibiotic free A549 cell
culture medium. A549 cells were cultured and seeded to 96-well
fluorescent microplates (5 × 104/well) 1 day before experiment.
DLF-1 labeled Mtb mutants and wild type control strains were
used to infect A549 cells at a MOI of 50. Fluorescence of the
microplates was measured to quantitate bacteria loaded initially.
After 3 h of infection, infected cells were washed once with
1X PBS, then added cell culture medium containing 200 µg/ml
amikacin and incubated for another 2 h to remove extracellular
bacteria. After aspirating amikacin containing medium and
washed with PBS solution, fluorescence of the microplates
were measured to quantitate intracellular bacteria. Bacterial
infection rate of each strain was calculated as the average
fluorescence intensity at the end of infection divided by the
average fluorescence at the beginning. Bacterial infection ratio of
mutant to wild type control is calculated as the mutant infection
rate divided by that of wild type strain. Bacterial samples from
the initial and end of infection were taken and plated for CFU
analysis.
RESULTS
DLF-1 is a High Affinity Stoichiometric
Probe for the D-Ala-D-Ala Motif of
Bacterial Peptidoglycan (PG)
The new fluorescent probe was designed to bind to the
terminal peptide D-Ala-D-Ala of the PG precursor. DLF-1
was synthesized by conjugating fluorescent Cy5.5 with glycyl-
vancomycin (Figure 1). Isothermal Titration Calorimetry (ITC)
was applied to verify that DLF-1 binds to the D-Ala-D-Ala motif
of PG. ITC measures the heat release (or absorption) associated
with a binding event, offering an orthogonal, non-fluorescence
based, validation of binding (Pierce et al., 1999). ITC shows that
DLF-1 binds stoichiometrically (N = 0.99) to the peptide Ac-L-
Lys-D-Ala-D-Ala (AcKAA) in PBS (Figure 2) with high affinity
(Kd 2.3 µM). The binding affinity for DLF-1 is similar to parent
molecule vancomycin (2.5 µM, Supplementary Table 1) and in
line with prior studies (Leavitt and Freire, 2001; Rekharsky et al.,
2006). These results suggest that DLF-1 has suitable biochemical
target binding properties to advance to microbial profiling.
DLF-1 Does Not Inhibit Growth of Bacteria
at the Working Concentration
In order to label actively growing bacteria, chemical probes
should not affect bacterial growth. We tested whether DLF-
1 labeling inhibits growths of M. smegmatis, M. bovis bacillus
Calmette-Guérin (BCG) andMtbCDC1551. Two concentrations
of DLF-1 were used to incubate with bacteria grown in liquid
media. The growth curves of bacteria incubated with two
concentrations of DLF-1 were compared with those without
DLF-1. OneµMof DLF-1 in culture media significantly inhibited
growth of M. smegmatis, while having much less of effect on
growth of M. bovis BCG and Mtb CDC1551. When 100 nM
DLF-1 was used, no significant effect on growth was observed
for Mtb (Figure 3). The MIC90 for DLF-1 against M. smegmatis
was determined as 1µg/ml (∼0.45µM) by broth microdilution
method. We then decided to use 100 nM of DLF-1 for the
remaining bacterial labeling.
DLF-1 Can Be Used to Accurately
Quantitate Mycobacteria In vitro
We have validated the application of DLF-1 to detection of
actively replicatingMtb in vitro, in comparison with fast-growing
M. smegmatis, and slow-growing M. bovis BCG. The correlation
between fluorescent signal and bacterial numbers was evaluated
after DLF-1 labeling of each Mycobacterium spp. Fluorescence
generated from DLF-1 labeling linearly correlated with bacterial
CFUs in all tested mycobacterial strains (Figure 4). The lowest
number of Mtb within the linear range is 5.3 × 104 (P < 0.05,
Figure 4D).
We also examined the threshold for differentiation of DLF-
1 labeled Mtb from the same number of Mtb without DLF-1
labeling using an optimal combination of excitation and emission
wavelengths and gain value set up in the multimode reader.
An Mtb strain carrying a plasmid expressing tdTomato was
used (Kong et al., 2016), and the tdTomato fluorescence served
as an internal control for DLF-1 labeling. When measured at
the optimal excitation and emission wavelengths of the Cy5.5
fluorophore on DLF-1, DLF-1 labeled Mtb showed significantly
higher fluorescence than the bacteria without labeling at each
dilution of bacteria (Supplementary Figure 2A). When measured
at the appropriate wavelengths for tdTomato, there was no
such a difference between the two groups at any dilution of
bacteria, suggesting there are the same bacterial numbers in the
two groups at each dilution (Supplementary Figure 2B). The
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FIGURE 1 | Structure of DLF-1. DLF-1 is synthesized by conjugating glycyl-vancomycin with a near infrared dye Cy5.5.
threshold of detection of Mtb for DLF-1 is ∼103 CFU using the
multimode plate reader with the optimal wavelengths and gain
value described in Materials and Methods (P < 0.05). Although
this condition can differentiate 103 CFU from the non-labeled
control, the detected fluorescence is not correlated with CFU very
well (R2 = 0.75).
DLF-1 Labeling Can Quantitate Mtb Inside
of Cells
We examined if DLF-1 could be applied to image Mtb in
cell infection models. A tdTomato-expressing Mtb strain was
incubated with DLF-1 and infected THP-1 macrophages and
A549 human lung epithelial cells. Fluorescence was detected from
MOI = 10 in both cell lines (Figure 5A), and the fluorescence
measured from DLF-1 labeled Mtb increased as MOIs rose. The
fluorescent intensity of endogenous tdTomato among different
MOI groups in A549 or THP-1 cells was measured in parallel
with fluorescence of DLF-1. Cell infection with DLF-1 labeled
Mtb was further verified by fluorescent microscopy. Slides with
fixed infected cells were imaged with a fluorescent deconvolution
microscope using pseudo colors: tdTomato-green, Cy5.5-red and
DAPI-blue. As shown in Figure 5B, tdTomato and Cy5.5 are co-
localized in cytoplasm of THP-1 and A549, which confirmed that
DLF-1 can be applied to detect labeledMtb inside of cells.
DLF-1 Can Label Non-replicating Dormant
Mtb In vitro
In order to study molecular mechanisms involved in the onset
of latency and/or reactivation, several in vitro and in vivomodels
have been developed tomimic LTBI in human. TheWaynemodel
developed in 1996 is a well-characterized in vitromodel based on
hypoxic growth ofMtb (Wayne and Hayes, 1996). In this model,
tubercle bacilli are cultured in an undisturbed liquid medium
and exposed to oxygen depletion by a way of a completely sealed
culture container. Mtb undergo an orderly process of metabolic
shutdown, and develop resistance to rifampicin and isoniazid,
but are sensitive to the anaerobic bactericide metronidazole
(Wayne and Lin, 1982; Wayne, 1994; Wayne and Hayes, 1996).
To validate DLF-1 in detecting dormantMtb, we labeled dormant
Mtb generated by the Wayne model with DLF-1.
AnMtb CDC1551 strain with a genome-integrated tdTomato
gene was used in the Wayne model to generate dormant Mtb.
With this strain, fluorescence of tdTomato can serve as an
internal positive control for DLF-1 labeling. The dormant state of
Mtb from this model was confirmed by verifying drug tolerance.
AfterMtb reached dormant state, 0.1 µg/ml rifampin was added
in the culture for 3 days. The proportion of survived dormant
Mtb reached 23.5 ± 4.8% (calculated as CFU of treated/CFU of
untreated), which is consistent with previously reported results
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FIGURE 2 | Thermodynamic evaluation of Ac-L-Lys-D-Ala-D-Ala-OH binding to DLF-1. Top: Raw curve of power vs. time. Bottom: Fit of integrated peak
areas (heat released per injection) used to determine the thermodynamic parameters presented in Supplementary Table 1. (A) Representative ITC data measuring
the thermodynamics of binding of peptide to Vancomycin. Peptide (600 µM) was titrated into a solution containing vancomycin (32 µM) in 1X PBS at 25◦C.
(B) Representative ITC data measuring the thermodynamics of binding of peptide to DLF-1. One percent of DMSO was added to control and test titrations, as it
increased solubility of DLF-1.
(Wayne and Hayes, 1996). With the same dose of rifampin,
97.5% of actively replicating Mtb was killed (Supplementary
Table 2).
After the hypoxic dormant bacilli were obtained, cultures
were washed with PBS, diluted into a series of concentrations,
and incubated with DLF-1. The bacteria were plated for CFU
enumeration. The fluorescent signal from labeled bacteria
was measured with a multimode plate reader, using Cy5.5
and tdTomato wavelengths, respectively. Correlation between
DLF-1 fluorescence and DLF-1 concentrations was analyzed
first to determine dose-response relationship of DLF-1 labeling
(Supplementary Figure 3A). The measured fluorescence
increased as the concentration of DLF-1 went higher. Correlation
between fluorescence and bacterial numbers was also analyzed
using DLF-1 and tdTomato wavelengths, respectively (Figure 6A
and Supplementary Figure 3B). Both DLF-1 specific fluorescence
and tdTomato fluorescence correlated very well with bacterial
CFUs. The threshold of detection for DLF-1 labeled dormantMtb
was determined as 3.1 × 105 CFU (Figure 6B). DLF-1 labeling
dormant Mtb was also confirmed with fluorescent microscopy
using a deconvolution microscope as shown in Figure 6C for
bacterial smear and in Figure 6D for intracellular dormant Mtb
in THP-1 cells. The red pseudo color from DLF-1 co-localized
with the green pseudo color from tdTomato very well both in
smear slides and in cell infection slides, which confirms that
DLF-1 is capable of labeling dormant Mtb, and the fluorescent
signal can be measured when bacteria are inside of cells.
DLF-1 Can Be Applied to Screen for Mtb
Genes Critical for Cell Invasion In vitro
Conventionally, identification of Mtb virulence genes relies on
comparison of bacterial CFUs between mutant and wild type
strains under specific conditions. DLF-1 labeling has great
potential to replace CFU enumeration in vitro. As DLF-1 labeling
can quantitate labeled Mtb inside cells, we set out to identify
bacterial genes that are critical for cell entry. Previous studies
have reported that the heparin-binding hemagglutinin (HbhA)
ofMtb plays an important role in infecting epithelial cells (Pethe
et al., 2001; Mueller-Ortiz et al., 2002; Parra et al., 2004; Choi
et al., 2013). HbhA was initially identified in Mtb and M. bovis
BCG (Menozzi et al., 1996, 1998). It is located on the surface
of the mycobacterium and mediates binding of the bacillus to
epithelial cells and fibroblasts (Menozzi et al., 1996). Deletion
of hbhA (∆hbhA) leads to reduced adherence of bacteria to
epithelial cells but shows no effect on adherence to macrophages
(Pethe et al., 2001). We evaluated entry rates of 1hbhA and
the wild type Mt103 strain in A549 human lung epithelial cells
using DLF-1 labeling, in comparison with CFU enumeration.
Infection ratios of 1hbhA to the wild type strain Mt103 at a
MOI of 50 was <1 based on both DLF-1 fluorescent intensity
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FIGURE 3 | Mycobacterial growth curves in the presence or absence of DLF-1. (A–C) represent the growth curve of each mycobacterium in media containing
0, 100 nM, 1 µM of DLF-1, respectively. (A) Mycobacterium smegmatis; (B) Mycobacterium bovis BCG; (C) Mycobacterium tuberculosis CDC1551. Error bars
represent standard errors of means calculated based on results from three independent experiments.
and CFU results (Table 1). The infection ratio calculated using
DLF-1 fluorescent intensity was consistent with the infection
ratio calculated using CFU, which suggests that DLF-1 can be
applied to screen bacterial genes that are critical for cell infection,
and the 1hbhA strain can serve as a positive strain for this
purpose.
Phospholipases are important bacterial virulence factors
(Titball, 1998). Among them, phospholipase C (Plc) is important
for replicating and cell-to-cell spread in mouse peritoneal
macrophages for Listeria monocytogenes (Camilli et al., 1991).
The Plc of Clostridium perfringenes is also named α toxin, which
is haemolytic and suppresses neutrophil respiratory burst by
disturbing host cell protein kinase C signaling (Terada et al.,
1999).Mtb has four Plc genes, designated plcA, B, C, and D. The
plcA, B, and C loci are clustered, while plcD is in a separated
region in the chromosome of Mtb CDC1551. Expression of plc
genes are upregulated at the 24-h post infection in macrophage
infections, but deletions of plc genes do not impair growth in the
human macrophage cell line THP-1. The plcABC triple mutant
and plcABCD quadruple mutants are both attenuated in the late
phase of mouse infection, indicating plc genes are important for
Mtb survival in hosts (Raynaud et al., 2002).
We obtained the plcC mutant from BEI Resources (Manassas,
VA) and examined its cell infection rate, in comparison to
the infection rate of wild type CDC1551 in A549 cells. The
bacterial infection ratio of plcC mutant to wide type CDC1551
was 0.7 ± 0.1 based on DLF-1 fluorescence intensity, and
was 0.5 ± 0.2 based on CFU enumeration (Table 1). These
results indicate that plcC is an important gene for Mtb
entering alveolar epithelial cells. The detailed mechanism of
how plcC helps bacilli infect epithelial cells remains to be
explored.
DISCUSSION
Bacterial cell walls are organized with layers of PG located
immediately outside of the cytoplasmic membranes (Scheffers
and Pinho, 2005; Shih and Rothfield, 2006; Silhavy et al.,
2010). PG is composed of a polysaccharide backbone along
with alternating N-acetylmuramic acid and N-acetylglucosamine
residues. These chains are then cross-linked via D-Ala-D-Ala
motifs by transpeptidases (penicillin binding proteins; Scheffers
and Pinho, 2005; Shih and Rothfield, 2006; Silhavy et al., 2010).
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FIGURE 4 | Direct labeling of different mycobacteria with DLF-1. Fluorescent intensities of DLF-1 labeled bacteria were plotted against the numbers of bacteria.
(A–C) represent plots for M. Smegmatis, M. bovis BCG, and Mtb CDC1551, respectively. Linear trend lines with R-squares are also displayed for each plot. Linear
range: M. smegmatis 4.3 × 105−4.3 × 107; M. bovis BCG 3.5 × 104−3.5 × 107; and Mtb 5.3 × 104−5.3 × 107. (D) Minimum number of Mtb within the
detectable linear range. **P < 0.01; *P < 0.05. Error bars represent standard errors of means calculated based on results from three independent experiments.
The peptide cross links are essential for providing structural
integrity and rigidity to the bacterial cell wall (Höltje, 1998;
Shih and Rothfield, 2006). Almost all bacterial cell walls contain
PG, but not all of them have the same structures. Gram-
positive bacteria have a thicker PG layer than Gram-negative
bacteria (Shockman and Barrett, 1983; Beveridge, 1999; Shih
and Rothfield, 2006; Silhavy et al., 2010). Like Gram-negative
bacteria, the PG cell wall layer of mycobacteria lies below an outer
membrane, comprised of arabinogalactan (AG), and mycolic
acids (MA), which are covalently linked together to form a
MA-AG-PG complex (Hett and Rubin, 2008). This MA-AG-PG
complex is the essential core of the mycobacterial cell wall and
often the target of many drugs used to combat mycobacteria.
Glycopeptide antibiotics such as vancomycin, teicoplanin, and
telavancin act by binding to the terminal peptide D-Ala-D-Ala of
PG precursors, and are widely used in the treatment of infections
caused by Gram-positive bacteria, especially MRSA (Reynolds,
1989; Finch and Eliopoulos, 2005; Pace and Yang, 2006; Butler
et al., 2014). Thus, the DLF-1 probe could be used to label
Gram-positive bacteria. Vancomycin and its analogs can bind to
the mycobacterial cell wall components PG and/or lipid II (MIC
of vancomycin against Mtb: 2µg/ml) (Lambert, 2002; Dinesh
et al., 2013; Soetaert et al., 2015). To tag vancomycin, fluorescent
molecules must be introduced at sites that do not interfere with
its ability to bind to PG precursors. Vancomycin has two amine
groups that are amenable to chemical modification. The amine
located on the disaccharide is more chemically reactive (Kahne
et al., 2005), and as the disaccharide is not involved in D-
Ala-D-Ala binding, we attached Cy5.5 to this amine group to
produce our probe, DLF-1. We verified that DLF-1 has a high
affinity for D-Ala-D-Ala independently using isothermal titration
calorimetry (ITC). Because this novel fluorescent labeling probe
has vancomycin as an anchor, it is critical to confirm that DLF-1
does not affect bacterial growth at the working concentration for
imaging. We have verified that 100 nM of DLF-1 does not affect
Mtb growth.
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FIGURE 5 | Imaging infection of human epithelial cell line (A549) and human macrophage cell line (THP-1) with DLF-1 (100 nM) labeled Mtb.
(A) Fluorescence detected from cells infected with DLF-1 labeled Mtb at different MOIs in vitro. Fluorescent intensities were measured for the labeled DLF-1 (Cy5.5)
and for the endogenous fluorescent tdTomato protein, respectively. Error bars represent standard errors of means calculated based on results from three independent
experiments. One-way ANOVA test was conducted for assessing overall differences among groups, and Turkey’s multiple comparison tests were applied to assess
differences between two groups. **P < 0.01; and ***P<0.001. (B) Images of DLF-1 labeled Mtb inside of cells. THP-1 and A549 were infected with a
tdTomato-expressing Mtb strain which has been labeled with DLF-1. Red, pseudo-colored DLF-1; Green, pseudo-colored tdTomato; and Blue, DAPI. White scale
bars represent 10 µm.
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FIGURE 6 | DLF-1 labeling of dormant Mtb cultured in Wayne model. (A) Correlation between fluorescence measured with DLF-1 wavelengths and bacterial
numbers of dormant Mtb. Mtb was labeled with DLF-1 at 100 nM. (B) Threshold detection of DLF-1 labeling dormant Mtb in culture. *P < 0.05. (C) DLF-1 (100 nM)
labeling dormant Mtb smeared on slides, and imaged with a fluorescent microscope. (D) Microscopy images of the DLF-1 (100 nM) labeled dormant Mtb strain
carrying a genome-integrated tdTomato gene inside of THP-1 macrophages. Red, Cy5.5; Green, tdTomato; Blue, DAPI stained nuclei.
TABLE 1 | Bacterial cell infection ratios of mutants to the parental wild
type strains calculated using DLF-1 labeling fluorescence and CFU,
respectively.
Mutant/Mt DLF-1a CFUb
1hbhA/Mt103 0.8 ± 0.1* 0.6 ± 0.3*
plcC mutant/CDC1551 0.7 ± 0.1* 0.5 ± 0.2*
Bacterial infection ratio = entry rate of mutant strain/entry rate of wild type strain.
Bacterial entry rate = intracellular bacterial fluorescence intensity or CFU measured after
infection/total bacterial fluorescence intensity or CFU measured before infection.
a Infection ratios measured based on DLF-1 fluorescence.
b Infection ratios measured based on CFU.
Values shown here represent the averaged ones from more than three independent
experiments (*Wilcoxon-Mann-Whitney U-test showed that P < 0.05 for each ratio from
independent experiments calculated by either DLF-1 or CFU based method).
Fluorescently labeled glycopeptide antibiotics have been used:
(1) to detect bacterial infections in vivo (van Oosten et al.,
2013), (2) to study the genes that control the biosynthesis of
peptidoglycan (Tiyanont et al., 2006), and (3) to investigate
cell wall synthesis in B. subtilis (Daniel and Errington,
2003). Recently, a study demonstrated that a fluorescent dye
IR800CW conjugated with vancomycin can be applied to image
Staphylococcus aureus infection in mice with a high specificity
for detection of Gram-positive bacterial infections (van Oosten
et al., 2013). We explored the application of the DLF-1 in
detecting active replicating and dormant Mtb, and found that
DLF-1 can effectively label both actively replicating and dormant
Mtb. Furthermore, we developed an approach to use DLF-
1 labeled Mtb to quickly screen for bacterial genes that are
important for infectious and nonphagocytic cells. Because the
DLF-1 imaging method does not require a recombinant strain,
it can be directly applied to an established mutant library to
study bacterial genes in vitro. This application of DLF-1 has
been verified by using the 1hbhA mutant of Mt103 strain. It is
well-known that HbhA is critical for Mtb infection of epithelial
cells (Pethe et al., 2001; Mueller-Ortiz et al., 2002; Parra et al.,
2004; Choi et al., 2013). CFU enumeration results confirm that
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deletion of the hbhA gene did impair bacterial infection in A549
cells, as reported previously (Pethe et al., 2001). Using 1hbhA as
a positive control, we have found by DLF-1 labeling and CFU
enumeration that another gene of Mtb, plcC, is also important
for bacterial entry of epithelial cells. To our knowledge, this is
the first report showing that plcC plays an important role for
infecting epithelial cells. The fact of mutant of hbhA or plcC
had reduced entry rates but was still able to enter epithelial cells
indicates that Mtb has other genes that compensate function
of HbhA or PlcC. As lung epithelial cells are the first barriers
to Mtb infection, how Mtb enters epithelial cells is very critical
for establishment of lung infection at earlier stages. It remains
to further explore the detailed mechanism of plcC in lung
infection and if the other three plc genes of Mtb share similar
function.
The novel fluorescent imaging method described here
provides a useful substitute for traditional time-consuming,
labor-intensive approaches of quantitating bacterial numbers
in TB research in vitro. However, at current stage, DLF-1
cannot be directly applied to TB diagnostic assays as it is not
a mycobacterial specific probe. It remains to be investigated if
DLF-1 is capable of in vivo imaging of Mtb infection in live
animal models and ex vivo imaging of infected organs. The
dye Cy5.5 on DLF-1 makes it ideal for in vivo imaging, as its
excitation and emission wavelengths are within the “near infrared
window,” in which the absorbance coefficients of hemoglobin
water and hemoglobin have less absorbance, so excitation
light can penetrate through the animal without significant loss
(Weissleder, 2001). In the future, we will validate the sensitivity,
reproducibility and accuracy of DLF-1, by quantitating bacterial
numbers in Mtb infection in vivo. We will also evaluate
application of this imaging technique to quantification of drug
response in anti-TB therapy. As DLF-1 labels both viable bacteria
and dead ones, it can be utilized together with other techniques
that measure viable bacteria only, such as fluorescence protein
expressing strains, to evaluate bactericidal activities in laboratory.
The dead bacterial number could be calculated as the number
of bacteria estimated by DLF-1 labeling subtracting the number
of bacteria estimated by measuring fluorescent intensity of
the fluorescence protein expressing strain. In summary, this
strategy could be applied to preclinical screening therapies in a
more time-efficient manner, and be used to real-time quantitate
bacterial load while studying bacterial genes and host immune
factors involved in active TB or LTBI. The success of these studies
would accelerate screening for anti-TB therapy in animal models
and enhance studies of bacterial and host factors in TB.
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